Eli Lilly and Company (NYSE:LLY) Trading 0% Higher

Eli Lilly and Company (NYSE:LLY) shares rose 0% on Tuesday . The company traded as high as $775.87 and last traded at $773.44. Approximately 438,481 shares changed hands during trading, a decline of 86% from the average daily volume of 3,223,609 shares. The stock had previously closed at $773.14.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Finally, Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Eli Lilly and Company Stock Performance

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $739.88 billion, a P/E ratio of 134.26, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34. The firm’s 50-day moving average is $727.96 and its two-hundred day moving average is $636.01.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.09 EPS. As a group, research analysts expect that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 195,055 shares of company stock worth $125,254,657. Company insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors have recently modified their holdings of the stock. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Retirement Group LLC raised its holdings in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the last quarter. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $29,000. Finally, Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.